Pharmacy Symposium 2018
5-9 March 2018

New Anatomy Lecture Room (NALR)
Biomedical Sciences Building
University of Malta

Programme

Oral Communication Sessions
Doctorate in Pharmacy Third Year Students
MPharm Students
M.Sc. Pharmacy Second Year Students
B.Sc. (Hons) Pharm.Tech Third Year Students

Poster Discussion Sessions
B.Sc. (Hons) Pharm.Sci Fourth Year Students

Poster Presentations
B.Sc. (Hons) Pharm.Sci Third Year Students
B.Sc. (Hons) Pharm.Sci Second Year Students
Monday 5 March

09.00 Opening Ceremony

Oral Communication Session: Doctorate in Pharmacy

10.10 Development of a Pharmaceutical Care Model within Paediatric Oncology
Sephorah Falzon

10.20 Implementation of a Pharmaceutical Care Model within Haematology
Diane Saliba

10.30 Pharmacist-led Discharge Service at Mater Dei Hospital
Denise Borg

10.40 Establishment of Pharmaceutical Services within the Emergency Department
Graziella Portelli

10.50 Interdisciplinary Impact of a Pharmacist-led Medication Safety Service
Dustin Balzan

11.00 COFFEE BREAK

11.30 Chronic Obstructive Pulmonary Disease Exacerbations- Cost, Risk factors and Impact of Long-Acting Muscarinic Antagonists
Jessica Spiteri

11.40 Access to Orphan Drugs and Quality of Life in Rare Diseases
Amar Ibraheem Abbas

11.50 Accessibility and Safety of Antipsychotics in the Treatment of Autism Spectrum Disorder in Children and Adolescents
Shaista Sadaf

12.00 Development of a Paediatric Intravenous Formulations Manual
Dania Al-Haddad

12.10 Aspirin and Novel Oral Anticoagulants: Reporting of Adverse Drug Reactions
Jessica Attard
Tuesday 6 March

09.15 Opening Session

**Oral Communication Session: Doctorate in Pharmacy**

09.20 Emerging Patterns in the Clinical Development of Medicines in Paediatric Oncology
*Benjamin Micallef*

09.30 Assessment of Medicinal Products: A Comparative Study between Europe and the United States of America
*Mathew Camilleri*

09.40 Risk Assessment of Dispensing Errors arising from Prescriptions in Malta and Germany
*Jeffrey Kupka*

09.50 Patient-Centred Regulatory Audits in Community Pharmacy
*Annalise Attard*

**Oral Communication Session: Master in Advanced Clinical Pharmacy**

10.00 Developing Safe and Effective Medicinal Products to Treat Leber Hereditary Optic Neuropathy: Clinical and Regulatory Challenges
*Marta Zuccarelli*

**Oral Communication Session: MPharm: Pharmaceutical Care**

10.10 Medication Use Management in a Long-term Elderly Care Setting
*Tiziana Fenech Caruana*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.20</td>
<td>Patient Monitoring with Use of Lithium</td>
<td>Julia Pirotta</td>
</tr>
<tr>
<td>10.30</td>
<td>Documentation of Prescribing Processes in a Long-term Psychiatric Setting</td>
<td>Roberto Briffa</td>
</tr>
<tr>
<td>10.40</td>
<td>Community Pharmacist Intervention in the Management of Older Persons</td>
<td>Rebecca Zammit</td>
</tr>
<tr>
<td>10.50</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Oral Communication Session: MPharm: Pharmacy Administration and Regulatory Affairs</strong></td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td>Public Perception and Expectations of Pharmacy Services</td>
<td>Yasmine Hefny Mohamed</td>
</tr>
<tr>
<td>11.40</td>
<td>Clinical Practice and Pricing Insights into Medicine Access Intelligence</td>
<td>Stefan Cassar</td>
</tr>
<tr>
<td>11.50</td>
<td>Improvements in the Registration of Medicines Process</td>
<td>Francesca Cilia</td>
</tr>
<tr>
<td>12.00</td>
<td>Buzz session</td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td>Closing</td>
<td></td>
</tr>
</tbody>
</table>

**Wednesday 7 March**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.15</td>
<td><strong>Opening Session</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Oral Communication Session: BSc Pharmaceutical Technology</strong></td>
<td></td>
</tr>
<tr>
<td>09.20</td>
<td>Ethics for Pharmaceutical Technologists</td>
<td>Christian Francalanza</td>
</tr>
<tr>
<td>09.30</td>
<td>The Pharmaceutical Technologist in the Government Pharmaceutical Services</td>
<td>Mark Spiteri</td>
</tr>
</tbody>
</table>
09.40 **Pharmaceutical Technology and Regulatory Affairs**  
*Melanie Xerri*

09.50 **Risk of Using Returned Medicines**  
*Jonathan Joseph Attard*

10.00 **Qualitative and Quantitative Analytical Methods for Drugs of Abuse**  
*Julia Mifsud*

10.10 **Structure Activity Relationships of Drugs of Abuse**  
*Kersty Axisa*

10.20 **Drug Stability**  
*Shanice Marie Spiteri*

10.30 **Use of Pesticides**  
*Pauline Falzon*

10.40 **Falsified Medicines through Online Purchase**  
*Luca Arrigo*

**10.50 COFFEE BREAK**

**Poster Communication Session: Pharmacy Information and Administration**

11.30 **Chronopharmacology in Disease Management**  
*Onyinyechi Chesa*

11.35 **Pharmacist Services in Community Pharmacies**  
*Rand Abdulrahman*

11.40 **Formulary for Non-BNF Cited Products**  
*Renita Busuttil*

11.45 **Health Economic Study of the Use of Warfarin**  
*Grazielle Camilleri*

11.50 **Professional Development Programmes for Pharmacists**  
*Catherine Anne Busuttil*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
</table>
| 11.55 | **Economic Impact of POYC Out-of-Stock Medication**  
*Charlene Bartolo* |
| 12.00 | **Buzz session** |
| 13.00 | **Closing** |

---

**Thursday 8 March**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.15</td>
<td><strong>Opening Session</strong></td>
</tr>
</tbody>
</table>
| 09.20 | **Oral Communication Session: MSc Pharmacy**  
*Aseptic Preparation of Medicines in the Hospital Pharmacy*  
*Stephanie Wonnacott* |
| 09.30 | **Accurate and Efficient Pharmaceutical Service Delivery through the Pharmacy of Your Choice Scheme**  
*Steven James Schiavone* |
| 09.40 | **Analytical Considerations in Testing Genetic Polymorphisms of Clinical Relevance**  
*Celine Psaila* |
| 09.50 | **Determination of Amitriptyline and its Metabolites from Blood**  
*Noeleene Mangion* |
| 10.00 | **Regulatory Science and Medicinal Cannabis**  
*Lara Sciberras* |
| 10:10 | **Comparing EMA and FDA GMP Requirements for the Production of Pharmaceuticals**  
*Mandy Muscat* |
| 10:20 | **The Impact of Medicinal Products Identifier on the Wholesale Distribution of Medicines**  
*Cristina Miceli* |
| 10.30 | **COFFEE BREAK** |
Oral Communication Session: MPharm: Medicinal Chemistry I

11.00 Identification and Optimisation of Leishmania Kinase Inhibitors  
Yasmin Caruana

11.10 \textit{in silico} Design and Optimisation of Polyphenolic Flavonoid Quercetin Analogs for Histone Deacetylase and Histone Acetyltransferase Inhibition  
Durston Delia

11.20 \textit{in silico} Design and Optimisation of Oleuropein and Lisinopril Analogs for MMP-9 Receptor Modulation  
Matthias Karl Farrugia

11.30 \textit{in silico} Design and Optimisation of Phytoalexin Resveratrol Polyphenolic Analogs for Histone Acetyltransferase Inhibition  
Rebecca Hammett

Poster Communication Session: Pharmaceutical Care and Point-of-Care

11.40 Seamless Pharmaceutical Care in Rheumatoid Arthritis Management  
Francesca Galea

11.45 Pharmacist-led Management of Insulin Therapy  
Jessica Zarb

11.50 Medicine Reconciliation at Discharge  
Thomas Zammit

11:55 Point-of-care Haemoglobin Measurement  
Martina Scicluna

12.00 Pharmacist Prescribing and Point-of-care Testing  
Tricia Micallef

12.05 Buzz session

13.00 Closing
Friday 9 March

09.15  Opening Session

**Oral Communication Session: MPharm: Medicinal Chemistry II**

09.20  *in silico* Design and Optimisation of Novel Human Glucocorticoid Receptor Modulators  
*Sean Meachen*

09.30  *in silico* Design and Optimisation of Poly (ADP-ribose) Polymerase Inhibitors using Olaparib as a Lead Molecule  
*Christopher Muscat*

09.40  Design and Optimisation of Epigallocatechin-3-gallate and Genistein Analogs for Histone Deacetylase Inhibition  
*Luke Xuereb*

**Poster Discussion Session: Medicinal Chemistry**

09.50  Rational Design of Structures Capable of Modulating Liver X Receptors for the Management of Pancreatic Cancer using the Agonist GW3965 Scaffold as a Lead Molecule  
*Nicole Bonello*

09.55  Design of Novel Protein Kinase Inhibitors Using the Naturally Occurring Isojacareubin Scaffold as a Lead  
*Jeanelle Caruana*

10.00  Design of Novel Structures Capable of Modulating the Steroid Receptor Co-activator for the Management of Neoplastic Disease  
*Ruth Fiorentino*

10.05  Design of Novel Protein Kinase Inhibitors Using the Naturally Occurring Staurosporine Scaffold as a Lead  
*Elena Maria Mallia*

10.10  Targeting the Kappa Opioid Receptor in the Treatment of Addiction  
*Maria Mangion*
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.15</td>
<td><strong>Rational Design of Novel Androgen Receptor Inhibitors Using the Experimental Small Androgen Receptor Modulators (S)-11 and (R)-9, and R-bicalutamide Scaffolds as Lead Molecules</strong>&lt;br&gt;Simona Svetlozarova Neykova</td>
<td></td>
</tr>
<tr>
<td>10.20</td>
<td><strong>Targeting the BCL-2 Receptor in the Management of Leukaemia and Other Solid Tumours</strong></td>
<td>Yvonne Savona Ventura</td>
</tr>
<tr>
<td>10.25</td>
<td><strong>Rational Design of Partial Peroxisome Proliferator Activated Receptor-γ Agonists Using the Synthetic Analog of Tetrahydrocannabinol, Ajulemic acid Scaffold as Lead Molecule</strong>&lt;br&gt;Kirby Zammit</td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Poster Communication Session: Pharmaceutical Technology and Forensics</strong></td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td><strong>3D Printing and Pharmaceutical Dosage Forms</strong></td>
<td>Christopher Johnson</td>
</tr>
<tr>
<td>11.05</td>
<td><strong>Forensic Pharmacy: Drugs and Driving</strong></td>
<td>Abigail Calleja</td>
</tr>
<tr>
<td>11.10</td>
<td><strong>Forensic Pharmacy: Drug Testing</strong></td>
<td>Michaela Cini</td>
</tr>
<tr>
<td>11.15</td>
<td><strong>Dosage Forms and Medicine Acceptability</strong></td>
<td>Maria Bartolo</td>
</tr>
<tr>
<td>11.20</td>
<td><strong>Closing Ceremony</strong></td>
<td></td>
</tr>
</tbody>
</table>
Third Year Student Projects

Rational Design of Novel Acid Ceramidase Inhibitors
*Gabriel Abela*

Rational Design of Novel $\mu$-opioid Antagonists Based on the PZM21 Scaffold
*Stephanie Attard*

Pharmacist-recommended Medicines for Paediatric Patients
*Chiara Baldacchino*

Rational Design of Glutathione-S-Transferase Pi1 (GSTP1) Antagonists Based on the Novel LAS17 Scaffold
*Gabriel Borg*

Rational Design of Proto-Oncogene Tyrosine-Protein Kinase SRC Antagonists Based on the Novel ECF506 Scaffold
*Lara Marie Busuttil*

Rational Design of Dual PPAR$\gamma$/\(\alpha\) Agonists Based on the Novel SR10171 Scaffold
*Justin Cassar*

Use of Antibacterial Drugs in the Intensive Care Unit
*Julia Catania*

Rational Design of Novel Structures Based on the Leiodermatolide Scaffold Capable of Tubulin Inhibition
*Graziella Chetchuti*

Rational Design of Novel Histone Deacetylase (HDAC) Inhibitors based on the AR-42 Scaffold
*David Gatt*

Use of the UM-164 Scaffold to Design Tyrosine-Protein Kinase SRC Inhibitors
*Thomas Sammut*

Repurposing Fluphenamic Acid and Glibenclamide for the Design of AKR1C1 Receptor Inhibitors
*Matthew Scicluna*

Rare Diseases and Orphan Medicines
*Sharon Vassallo*
Determination of Orthoesterification Mechanisms in Drug Synthesis  
*Maria Xiberras*

Use of Newer Generation Statins in Cardiovascular Disease  
*Maia Zarb*

---

**Second Year Student Projects**

**Repurposing the Methotrexate Scaffold to Design Novel Janus Kinase Inhibitors**  
*Francesca Borg*

**Design of Novel CU-CPT8M Analogs to Modulate the Toll-Like Receptor 8 Dimer**  
*Claire Bugeja*

**Repurposing the Anthelmintic Drug Niclosamide for the Rational Design of pten-induced Putative Kinase 1 Agonists**  
*Abigail Buttigieg*

**Cultivation of Cannabis**  
*Miriana Cachia*

**Outcomes of Pharmacist-Led Medication Use Review for Patients with Respiratory Disease**  
*Christy Caruana*

**Risk with Use of Medical Cannabis**  
*Michael Cini*

**Identification of Potential Endogenous Targets for Maltanedienol**  
*Ella Coppini*

**Rational Design of Phosphoinositide 3-Kinase Modulators**  
*Hannah Coppini*

**Pharmaceutical Care for Stem Cell Transplant Patients**  
*Krysta Cutajar*

**The Unique Identifier on Drug Products**  
*Mireille Debono*
Pharmaceutical Interventions During Labour
Rebecca Marie Falzon

Pharmaceutical Care in Paediatric Oncology
Sarah Marie Falzon

Pharmaceutical Care Interventions in Obstetrics and Gynaecology
Naomi Fiteni

Design of BRD9 Receptor Antagonists Based on the BI-7273 Scaffold
Paula Gambin

Design of Androgen Receptor Inhibitors Using the Naturally Occurring Capsaicin Scaffold as a Lead Molecule
Johan Grech

Design of BU10119 Analogs for the Management of SSRI Refractory Depression
Matthew Grech

Risk-based Processes in Pharmacy Practice
Emily Magro

Evaluation of Anaesthetic Drugs in the Intensive Therapy Unit
Julia Micallef

Outcomes of Pharmacist-Led Medication Use Review for Diabetics
Mathea Montebello

Smoking Cessation in Post-hospitalisation Rehabilitation
Gabrielle Scicluna

Design of 6-Phosphogluconate Dehydrogenase (6PGD) Inhibitors Using Parietin, and its Semi-Synthetic Derivative S3 Scaffolds as Lead Molecules
Daniel Sinagra

Simplification of the Experimental Molecule FR900359
Brandon Sultana

Patient Education and Medication Compliance in Osteoporosis
Michaela Vella

Rational Design of Glutaminase c Modulators
Lara Zammit